Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

RegeneRx Announces New Board Member

PR Newswire March 21, 2019

RegeneRx Closes $1.3 Million Convertible Debt Financing

PR Newswire February 27, 2019

RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259

PR Newswire February 12, 2019

RegeneRx Update on Dry Eye and EB Clinical Trials

PR Newswire January 4, 2019

RegeneRx Partner Updates on Clinical Trials

PR Newswire October 29, 2018

World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin"

PR Newswire September 6, 2018

RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa

PR Newswire August 2, 2018

RegeneRx Holds Annual Meeting

PR Newswire June 13, 2018

RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018

PR Newswire May 29, 2018

ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO

PR Newswire May 2, 2018

GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

PR Newswire April 25, 2018

RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

PR Newswire April 9, 2018

RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds

PR Newswire March 14, 2018

RegeneRx Secures $1 Million in Funding

PR Newswire March 2, 2018

Key U.S. Dry Eye Patent Issued to RegeneRx

PR Newswire February 22, 2018

RegeneRx Releases Annual Letter to Shareholders

PR Newswire December 7, 2017

Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium

PR Newswire November 16, 2017

RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial

PR Newswire October 31, 2017

RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.

PR Newswire September 13, 2017

RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia

PR Newswire August 31, 2017